| » |
Xcovery's knowledge of kinase technology has demonstrated the ability to discover and develop validated leads with superior drug properties in shorter periods of time and with lower risk than comparable efforts. |
| |
|
| » |
Xcovery can develop preclinical lead candidates with properties superior to existing lead compounds in less than 18 months. |
| » |
The Xcovery approach (VIRDD*) produces inhibitors with greatly reduced toxicity, as Xcovery inhibitors target only the diseased cells. |
|
|
| » |
Xcovery is building a team with the best in kinase medicinal chemistry, the best of early stage biotechnology management, and the highest value creation to develop targeted, less toxic therapies as proprietary efforts and with biopharma partners. |
|
| |
| *VIRDD : Vertically Integrated Rational Drug Design |
| |
|